A global clinical trial, led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute, has found that adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer.
